Rein Therapeutics, Inc. Common Stock
RNTXRein Therapeutics, Inc. (RNTX) is a biopharmaceutical company focused on developing therapies targeting neurodegenerative diseases. The company's research emphasizes innovative approaches to treat conditions such as Parkinson’s disease and other neurodegenerative disorders, leveraging advances in molecular biology and drug delivery technologies.
Company News
Rein Therapeutics completed a $57.5 million underwritten public offering of common stock, including full exercise of the over-allotment option. The company will use net proceeds to fully fund its Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis and support operations into Q1 2028. The offering was backed by healthcare-focused inves...
Rein Therapeutics priced a public offering of 50 million shares at $1.00 per share, raising $50 million in gross proceeds. The company plans to use net proceeds to fully fund its Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis and for working capital. Based on current operating plans, the company believes the proceeds combined ...
The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designation...
Rein Therapeutics received UK regulatory approval to launch a Phase 2 clinical trial for LTI-03, a potential breakthrough treatment for idiopathic pulmonary fibrosis (IPF), targeting fibrosis and lung tissue regeneration.
Rein Therapeutics will present two scientific talks at the IPF Summit 2025, discussing their novel approach to treating idiopathic pulmonary fibrosis (IPF) through innovative molecular research and clinical trial design.
